Zacks Research Has Positive Forecast for CRSP Q2 Earnings
Equities researchers at Zacks Research upped their Q2 2025 earnings estimates for CRISPR Therapeutics in a report issued on ...
Shareholders in CRISPR Therapeutics (NASDAQ:CRSP) are in the red if they invested a year ago
Investors in CRISPR Therapeutics AG (NASDAQ:CRSP) have tasted that bitter downside in the last year, as the share price dropped 46%. That contrasts poorly with the market return of 15%. At least the ...
Zacks.com on MSN5d
CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know
CRISPR Therapeutics (CRSP) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Analysts Set Expectations for CRSP FY2027 Earnings
Analysts at Zacks Research issued their FY2027 earnings per share (EPS) estimates for CRISPR Therapeutics in a report ...
CRISPR Therapeutics AG (CRSP): the Most Oversold Pharma Stock to Buy According to Analysts
We recently published a list of the 10 Oversold Pharma Stocks to Buy According to Analysts. In this article, we are going to ...
CRISPR Therapeutics AG (CRSP) TD Cowen 45th Annual Healthcare Conference (Transcript)
CRISPR Therapeutics AG ( NASDAQ: CRSP) TD Cowen 45th Annual Healthcare Conference March 3, 2025 10:30 AM ET ...
6 Vanguard Index Funds To Buy Now
Explore highly-rated Vanguard index funds for long-term investing and build a well-diversified portfolio. Check our list of ...
Nasdaq10d
Insider Purchase: Director at $CRSP Buys 7,000 Shares
John Greene, a director at $CRSP, bought 7,000 shares of the company on 02-26-2025 for an estimated $313,947. This trade was reported by Quiver Quantitative using ...